China’s CSPC Pharmaceutical Group and UK-based AstraZeneca formed a strategic collaboration and license agreement focused on CSPC’s innovative long-acting peptide medicines, anchored by CSPC’s sustained-release delivery technology and AI-driven peptide discovery platform. The deal includes rights to the once-monthly injectable obesity candidate SYH2082 (a GLP-1R/GIPR agonist) for weight management and weight-related conditions, as well as up to seven other molecules.

Under the deal, AstraZeneca secures exclusive global rights outside Greater China (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan), in return for an upfront payment of USD 1.2 billion to access the eight CSPC programs and underlying platforms. CSPC is also eligible for up to USD 3.5 billion in potential research and development milestones and up to USD 13.8 billion in potential sales milestones, plus up to double-digit royalties on annual net sales of licensed products.

The licensed package includes CSPC’s once-monthly injectable weight management portfolio: SYH2082 (described as “clinical-ready” and progressing into Phase I) plus three preclinical programs with undisclosed, differing mechanisms. The parties also agreed to collaborate on four additional new programs leveraging CSPC’s delivery and AI discovery platforms.

Industry context

AstraZeneca is building on an existing relationship with CSPC, having first licensed a cardiovascular candidate from the Chinese firm in June 2024 in a deal worth just north of USD 2 billion, followed by a research alliance focused on AI-driven drug discovery for chronic and immunological diseases signed in June 2025, the latter worth over USD 5 billion in total commitments.

This week’s deal rivals Merck & Co.’s USD 22 billion partnership with Daiichi Sankyo for three antibody drug conjugates (signed in 2023) as one of the biggest global licensing deals ever signed. It also means AstraZeneca has one of the most extensive obesity/metabolic disease pipelines outside of Eli Lilly and Novo Nordisk.

The last two years have seen a string of licensing and M&A deals in the obesity therapeutic space, led by Pfizer’s USD 10 billion acquisition of Metsera (November 2025), Roche’s USD 5.3 billion license deal with Zealand Pharma (March 2025) and USD 3.5 billion acquisition of Carmot Therapeutics. AstraZeneca’s CSPC partnership is just the latest for the UK firm in the obesity space, following a USD 2 billion license deal with China-based Eccogene signed in 2023 for a daily oral GLP-1 agonist, and the USD 300 million purchase of Six Peaks completed in October 2025 focused on a bispecific antibody targeting activin type IIA and IIB receptors.